Recent developments include the launch of the OneTest for Longevity blood test and securing a U.S. license for advanced chronic kidney disease prediction technology, reflecting product portfolio expansion and technology licensing progress.

• 20/20 Biolabs secured a U.S. license for advanced chronic kidney disease (CKD) prediction technology, expanding its diagnostic capabilities [N1].
• The company launched the OneTest for Longevity blood test in February 2026, targeting inflammatory biomarkers related to chronic disease and workplace wellness [N2].

The company offers a relatively affordable, AI-enhanced multi-cancer early detection test with demonstrated sensitivity for early-stage cancers, addressing a significant unmet medical need. Its proprietary protein biomarker approach may provide advantages over more expensive ctDNA-based tests. The launch of the OneTest for Longevity and securing a U.S. license for advanced CKD prediction technology diversify its product portfolio. Established supply contracts and a CAP-accredited, CLIA-licensed lab support operational reliability. The Clinical Laboratory Innovation Accelerator (CLIAx) could foster partnerships and expand offerings. Growing awareness and legislative support for MCEDs, such as Medicare coverage pathways and firefighter reimbursement programs, may enhance market acceptance.

The company operates in a highly competitive and rapidly evolving diagnostics market with established players offering alternative MCED technologies. Supply chain risks exist due to reliance on limited reagent and device manufacturers. Limited sales and marketing resources may constrain commercial growth and customer acquisition. The company has a history of operating losses and depends on external financing, which may dilute shareholders or be unavailable on favorable terms. Regulatory and reimbursement uncertainties persist, and the effectiveness of new products like OneTest for Longevity and CKD prediction technology remains to be fully demonstrated in the U.S. market. Potential disruptions in lab operations or technology transitions could impact test availability and revenue.

20/20 Biolabs' moat is anchored in its patented AI-powered multi-cancer early detection test that leverages protein tumor markers, which have demonstrated higher sensitivity for early-stage cancers compared to ctDNA-based competitors. The company's CAP-accredited, CLIA-licensed laboratory and established reagent supply contracts with major providers like Roche and Abbott provide operational stability. Its exclusive U.S. license for BioInfra's test panel and algorithm adds proprietary technology advantage. The company's 'top of funnel' test positioning, affordability under $200, and ease of access via capillary blood collection devices further differentiate it. Additionally, the Clinical Laboratory Innovation Accelerator (CLIAx) offers a unique platform for overseas startups, potentially expanding its ecosystem. However, supply chain dependencies and limited sales resources temper the moat strength.

• Supply Chain Dependence: The company relies on a limited number of suppliers for critical reagents and blood collection devices, with potential disruptions or price increases posing risks to test availability and cost structure.
• Limited Sales and Marketing Resources: Current sales and marketing capabilities are limited, which may hinder the company's ability to scale commercial adoption and compete effectively in the diagnostics market.
• Competition: The diagnostics market, especially for multi-cancer early detection, is highly competitive with rapid technological advances and established players offering alternative tests that may be safer, more effective, or more convenient.
• Financial Losses and Financing Needs: The company has incurred losses historically and anticipates continuing losses, relying on external financing to support operations, which may dilute existing shareholders or be unavailable on favorable terms.
• Regulatory and Reimbursement Uncertainty: The company faces risks related to obtaining and maintaining regulatory approvals and securing reimbursement coverage, which are critical for commercial success.

• 20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for early detection and prevention of cancers and chronic diseases.
• The company offers two main test families under the OneTest brand: OneTest for Cancer (multi-cancer early detection, MCED) and OneTest for Longevity (measuring inflammatory biomarkers), launched in February 2026.
• Both tests are performed in a CAP-accredited, CLIA-licensed laboratory in Gaithersburg, MD, which also hosts the Clinical Laboratory Innovation Accelerator (CLIAx) for overseas diagnostic startups.
• Legacy business includes BioCheck, a field test kit for screening suspicious powders for bioterror agents, contributing a small but positive cash flow.
• For the year ended December 31, 2025, OneTest for Cancer accounted for approximately 88% of revenues, BioCheck 8%, and CLIAx 4%.
• OneTest for Cancer is positioned as a 'top of funnel' screening test with a starting price under $200, significantly lower than competitors like Grail's Galleri test priced around $950.
• The OneTest uses protein tumor markers (PTMs) combined with patient information and AI algorithms to detect cancers at earlier stages, with demonstrated sensitivity in studies including a 2024 NCI-sponsored blinded validation.
• OneTest Premium includes additional inflammatory and metabolic biomarkers and provides likelihood estimates for eight specific tumor types.
• The company has reagent supply contracts with Roche and Abbott, ensuring pricing stability and supply chain reliability for immunoassay and chemistry markers.
• The company relies on Roche Diagnostics IVD kits for Cobas E411 analyzers and has alternative sourcing plans for certain assays to mitigate supply risks.
• The company has limited sales and marketing resources and contracts with about 1,000 retail establishments for blood draw services, including Any Lab Test Now and My One Medical Source.
• Approximately two-thirds of customers use capillary blood collection devices, which are FDA-cleared but sourced from a limited number of manufacturers, posing supply risk.
• The company has exclusive U.S. commercialization rights for BioInfra Life Science's test panel and algorithm for OneTest Premium, with a three-year license term potentially extendable.
• The company reported revenue of approximately $2.05 million and a net loss of about $3.74 million for the year ended December 31, 2025.
• Liquidity ratios as of December 31, 2025, include a current ratio of 0.6 and a cash ratio of 0.42, with cash and equivalents of approximately $1.03 million.
• The company has incurred losses historically and anticipates continuing losses in the near term, with recent capital raises including a direct Nasdaq listing in February 2026.
• The company faces competition from other MCED providers, including ctDNA-based tests like Grail's Galleri, which are more expensive and have lower sensitivity for early-stage cancers.
• The company emphasizes affordability, earlier stage cancer detection accuracy, accessibility, and AI compatibility as competitive advantages.
• Recent news includes securing a U.S. license for advanced chronic kidney disease (CKD) prediction technology and launching the OneTest for Longevity blood test in February 2026.
• The company operates under regulatory standards including CLIA and CAP, with biennial inspections and quality control measures in place.
• The company has risks related to supply chain disruptions, limited sales and marketing resources, competition, regulatory compliance, and the need for additional financing to support operations.